(CercleFinance.com) – Visiomed Group’s new strategic plan received a mixed reception on the Paris Stock Exchange on Wednesday, with some analysts deeming the group’s outlook for connected medical devices disappointing.
At 11:00 a.m., the title of the connected health specialist lost 4.3% and clearly underperformed a Parisian market which rose at the same time by 0.1%.
The title nevertheless continues to show a more than doubling of its share price since the beginning of the year.
Visiomed, which detailed last night its vision for the coming years, explained that it was aiming for an acceleration of its value creation under the impetus of three main axes, in this case the growth of its subsidiaries, the realization of structuring acquisitions and the activation of synergies.
Its subsidiary Smart Salem – which operates the only digital medical center in Dubai – thus has a major growth target for its core
profession, the medical test allowing residence in the United Arab Emirates.
Thanks to the opening of a second center in August 2022, the subsidiary should post a ‘pro forma’ turnover of 22.2 million euros this year, for an EBITDA of 12.2 million, i.e. a rate margin of 55%.
But, in a research note, analysts at Invest Securities highlight the ‘gloomy’ outlook for Bewell Connect, the connected medical devices business.
In its press release, Visiomed indeed recognizes that the ‘erratic’ performance and the losses of its entity encourage the realization of a complete diagnosis and a reflection on the redeployment of the company, with in the background a background work on cost control.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
